Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

Inclusion Criteria: * Males and postmenopausal females, 18 years or older * Advanced solid tumors with histologic diagnosis confirming cancer * Patients with recurrent metastatic or locally advanced disease considered refractory or intolerant to all standard treatment available for their tumor, or those tumors for which no standard treatment is available * Subjects with serous ovarian/fallopian tube/primary peritoneal, granulosa cell tumors or clear cell tumors considered platinum refractory/resistant, defined as having at least one prior platinum-based chemotherapeutic regimen with a subsequent platinum-free interval of \< 12 months, having progression during platinum-based therapy, or having persistent disease after a platinum-based therapy, are eligible. Intolerant subjects, defined as unable to receive further platinum due to toxicity, are eligible. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Informed consent Exclusion Criteria: * History of gastrointestinal bleeding within the past 6 months * History of epistaxis requiring medical/surgical intervention (such as nasal packing) within the past 6 months * History of central nervous system hemorrhage * History of bleeding diathesis or known qualitative platelet defect (including von Willebrand disease) * Ongoing need for therapeutic anticoagulants (full dose heparin, warfarin, factor Xa or direct thrombin inhibitors; rivaroxaban, apixaban, dabigatran) chronic use of aspirin or anti-platelet …